US$959.5 million, +61.4% year-on-yearGross profit: US$553.2 million, +103.3% year-on-yearAdjusted net profit: US$230.3 million, +285.0% year-on-yearBusiness Units' PerformanceGenScript Life Science ...
The company seeks to leverage the benefits of estrogen signaling to prevent age-related diseases and improve the “healthspan" as part of a new ARPA-H program.
DARE-PTB1 is a novel, investigational IVR designed to deliver bio-identical progesterone continuously for up to a 14-day period. It is being developed to reduce the risk of preterm birth in at-risk ...
Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026• DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options• Award ...
Investor attention is also tilting toward strategic minerals, including rare earths, copper and antimony. Read more at ...
In life sciences, enterprise value only emerges when generative AI is treated as a business capability and embedded into existing operating models.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results